Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 14, 611 (2008)
doi:10.1038/nm0608-611
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
There is an Erratum (July 2008) associated with this News and Views.
Community corner
New findings call into question the premise behind prominent clinical trials testing small interfering RNA (siRNA) against age-related macular degeneration, a leading cause of blindness. In these trials, researchers aim to ease symptoms by knocking out expression of vascular endothelial growth factor (VEGF) or its receptor, which contribute to growth of excess blood vessels in this disease.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Effect of 2,3-dimercaptosuccinic acid on nephrosclerosis in the Dahl rat. I. Role of reactive oxygen speciesKidney International Original Article
